This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs
by Zacks Equity Research
Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.
Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA
by Zacks Equity Research
Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.
AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business
by Zacks Equity Research
AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.
Bristol Myers (BMY) Gets FDA Nod for Data Addition to Camzyos
by Zacks Equity Research
Bristol Myers (BMY) receives FDA approval for additional data to be added to the label of the heart drug Camzyos.
Roche (RHHBY) Gets FDA Approval for Blood Cancer Drug Columvi
by Zacks Equity Research
Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Acadia Healthcare (ACHC) Expands With New Hospital in Michigan
by Zacks Equity Research
Acadia Healthcare's (ACHC) partnership with Bronson Healthcare to expand its footprint in Michigan with Bronson Behavioral Health Hospital.
Wall Street Analysts See a 44.32% Upside in Ligand (LGND): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 44.3% upside potential for Ligand (LGND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2seventy (TSVT) Down 9% on Patient Death in Leukemia Study
by Zacks Equity Research
Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.
Journey Medical (DERM) Up on Rosacea Candidate's Positive Data
by Zacks Equity Research
Journey Medical's (DERM) phase I study, assessing the impact of DFD-29 on the microbial flora of healthy adults, obtains its primary endpoints.
Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why
by Zacks Equity Research
Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug in patients with B-cell non-hodgkin's lymphoma and multiple myeloma.
First Wave (FWBI) Surges 33% on Finishing Enrolment in CF Study
by Zacks Equity Research
First Wave (FWBI) completes enrolment in a mid-stage study evaluating its investigational oral capsule in patients with cystic fibrosis. Topline data from the study is expected next month.
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.
Roche (RHHBY) Announces Positive Results From PNH Studies
by Zacks Equity Research
Roche (RHHBY) crovalimab achieves disease control in paroxysmal nocturnal hemoglobinuria patients in the phase III COMMODORE 1 and COMMODORE 2 studies.
Novartis (NVS) Sandoz Presents Standalone Growth Strategy
by Zacks Equity Research
Novartis generic arm, Sandoz, which will be spun off, expects strong growth as a standalone company, driven by increasing contribution from biosimilars.
Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ligand Pharmaceuticals (LGND) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Intercept (ICPT) Announces Positive Data From PBC Study
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.
Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA
by Zacks Equity Research
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.
LGND or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health
by Zacks Equity Research
UnitedHealth (UNH) offers to combine its Optum business with Amedisys to expand its reach in the healthcare-at-home market.
Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.
Novartis Announces Positive Data on Breast Cancer Drug Kisqali
by Zacks Equity Research
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
by Zacks Equity Research
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
by Zacks Equity Research
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
by Zacks Equity Research
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.